Search results
Results From The WOW.Com Content Network
para-Methoxyamphetamine (PMA), also known as 4-methoxyamphetamine (4-MA), is a designer drug of the amphetamine class with serotonergic effects. [2] [3] [4] Unlike other similar drugs of this family, PMA does not produce stimulant, euphoriant, or entactogen effects, [5] and behaves more like an antidepressant in comparison, [6] though it does have some psychedelic properties.
para-Methoxymethamphetamine (PMMA), also known as 4-methoxy-N-methylamphetamine (4-MMA), is a serotonergic drug of the amphetamine family related to para-methoxyamphetamine (PMA). It is the 4- methoxy analogue of methamphetamine .
Substituted amphetamines, or simply amphetamines, are a class of compounds based upon the amphetamine structure; [1] it includes all derivative compounds which are formed by replacing, or substituting, one or more hydrogen atoms in the amphetamine core structure with substituents.
An assortment of several designer drugs. Designer drugs are structural or functional analogues of controlled substances that are designed to mimic the pharmacological effects of the parent drug while avoiding detection or classification as illegal.
para-Ethoxyamphetamine, also known as 4-ethoxyamphetamine (4-ETA), is a psychoactive drug and research chemical of the phenethylamine and amphetamine chemical classes which is closely related to the infamous para-methoxyamphetamine (PMA). para-Ethoxyamphetamine has similar effects to PMA in animal studies, although with slightly weaker ...
Methoxyamphetamine may refer to: 2-Methoxyamphetamine (2-MA) ... 4-Methoxyamphetamine (4-MA) or para-methoxyamphetamine (PMA) See also. Dimethoxyamphetamine;
Average Cost of Pet Insurance in 2024. ... Cats. Comprehensive Plan: $383.30 ($31.94/month) ... Pet insurance isn’t free—average annual premiums amount to a few hundred dollars—but it can ...
4-Methylthioamphetamine (4-MTA), also known as para-methylthioamphetamine (MTA), is a designer drug of the substituted amphetamine class developed in the 1990s by a team led by David E. Nichols, an American pharmacologist and medical chemist, at Purdue University. It acts as a non-neurotoxic highly selective serotonin releasing agent (SSRA) in ...